Telix Pharmaceuticals Hosts Capital Markets Day in Melbourne on 4 November 2026

Shwetambri Chauhan

04 November 2026 10:15 AM AEDT

Telix Pharmaceuticals Hosts Capital Markets Day in Melbourne on 4 November 2026

Image Source: Krish Capital Pty Ltd

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Telix Pharmaceuticals Limited (ASX:TLX) held a Capital Markets Day in Melbourne, Australia on 4 November 2026, presenting information on its radiopharmaceutical business, approved products, and pipeline candidates including Zircaix and Pixlumi, which the company disclosed remain investigational and subject to final regulatory approval.

Key Points

Telix Pharmaceuticals held its Capital Markets Day in Melbourne, Australia on 4 November 2026.
Approved products include Illuccix® (gallium-68 gozetotide injection), Gozellix®, Pixclara® (floretyrosine F 18), Scintimun® (approved in 32 European countries and Mexico), and SENSEI® surgical gamma probe.
Pipeline candidates Zircaix and Pixlumi are described as investigational or under development and not approved by any regulatory authority; their brand names and launch are subject to final regulatory approval.
The company stated that no other Telix drug or device beyond those specifically identified has received marketing authorisation in any jurisdiction.

Approved Product Portfolio

According to the filing, Telix's first-generation PSMA-PET imaging product, Illuccix® (gallium-68 gozetotide injection, also known as 68Ga PSMA-11), has been approved in multiple markets globally, with the FDA also approving Gozellix® (kit for the preparation of gallium-68 gozetotide injection). The FDA has additionally approved Pixclara® (floretyrosine F 18), Telix's glioma imaging agent. Scintimun® (technetium-99m besilesomab), the company's osteomyelitis imaging agent, is approved in 32 European countries and Mexico. The SENSEI® miniaturised surgical gamma probe is registered with the FDA and holds a CE Mark for use in the European Economic Area.

Investigational Pipeline Candidates Zircaix and Pixlumi

The filing disclosed that Zircaix and Pixlumi are investigational or under development and have not been approved by any regulatory authority. The efficacy or safety profile of either product has not been determined by any regulatory authority, the filing stated. Additionally, the Zircaix and Pixlumi brand names and their launch are subject to final regulatory approval. The presentation was accompanied by standard forward-looking statement disclosures noting that actual results may differ materially from those expressed or implied by forward-looking statements included in the Capital Markets Day materials.

Non-IFRS Financial Measures Disclosed

The Capital Markets Day presentation included non-IFRS financial information to reflect underlying performance. The filing stated that these non-IFRS measures, which include Adjusted EBITDA — defined as net earnings attributable to the Group excluding finance costs, income tax expense, depreciation and amortisation, remeasurement of provisions, other income and expenses — have not been subject to audit or review. The company stated that reconciliations of non-IFRS financial measures to the most directly comparable IFRS measures have been provided as required by SEC rules, and that such non-IFRS measures are not a substitute for or superior to IFRS measures.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.